Engineered stem cells aim to speed recovery in blood cancer patients

NCT ID NCT04260698

Completed Disease control Sponsor: Gamida Cell ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests omidubicel, an experimental stem cell transplant, for people with high-risk blood cancers like leukemia or lymphoma. The goal is to see if it helps the body rebuild its immune system faster after transplant. Participants receive omidubicel along with standard transplant care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: omidubicel (stem cell transplant)
What this could lead to: If successful, omidubicel could help patients with blood cancers recover their immune system faster after a stem cell transplant, potentially reducing complications.
What could go wrong: This is an early expanded access study with a small number of participants. The treatment may not work for everyone, and stem cell transplants carry risks like infection and graft failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGICAL MALIGNANCIES

Contacts and locations

Locations

Duke University Medical Center

Durham, North Carolina, 27710, United States
Loyola University, Cardinal Bernardin Cancer Center

Maywood, Illinois, 60153, United States
Oregon Health & Science University

Portland, Oregon, 97239, United States
Stanford University Cancer Institute

Palo Alto, California, 94063, United States
UCLA

Los Angeles, California, 90095, United States
University of Minnesota Masonic Cancer Center

Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.